9 October, 2020
Review: Immune Response in Patients (Advanced Therapies)
CREATIO PUBLISHES THE FIRST SCIENTIFIC REVIEW ON THE IMPACT OF THE IMMUNE RESPONSE IN PARKINSON'S AND HUNTINGTON’S PATIENTS TREATED WITH CELL THERAPY, EVALUATING CLINICAL TRIALS CONDUCTED IN THE PAST FOUR DECADES
Cell therapy as a strategy to treat neurodegenerative diseases was first applied in humans in the 1980s. Since then, researchers and doctors around the world have continued to join forces to improve this treatment, which aims to replace affected neurons as well as enhance endogenous proliferation of new ones.
The latest review published by Creatio team, first-authored by the researcher Cristina Salado-Manzano, describes a detailed analysis of the mechanisms that promote Parkinson’s and Huntington’s diseases, which justify intracerebral transplantation since these diseases have no cure.
There is a crucial factor so that the transplanted tissue can integrate into the brain and be functional: the patient’s own immune response. In this work, the potential of cell therapy to reestablish the affected neural circuits in neurodegenerative diseases is demonstrated, although the immunosuppression pharmacological regimen, as well as the immune response biomarkers, would need to be further homogenized to improve the therapy.
The last part of this very complete review is a gift for those biomedicine lovers with special passion for biotech; would it be possible to develop an in vitro immunogenicity testing platform that allows to evaluate the activation of the immune system of a given cellular product, before even going to preclinical testing in animals? Advanced techniques and brilliant ideas will give an answer. Without a doubt, a good read that offers a thorough overview of a complex strategy that carries encouraging potential for the treatment of neurodegeneration.
Cristina Salado-Manzano has been a PhD Student of the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement no 722779, Training4CRM.